A Child With Lymphangioma Due to Somatic Mutation in PIK3CA Successfully Treated With Everolimus

Pediatr Neurol. 2019 Feb:91:65-67. doi: 10.1016/j.pediatrneurol.2018.10.017. Epub 2018 Nov 22.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Child
  • Class I Phosphatidylinositol 3-Kinases
  • Everolimus / pharmacology*
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / genetics*
  • Humans
  • Lymphangioma / drug therapy*
  • Lymphangioma / genetics*
  • Male

Substances

  • Antineoplastic Agents
  • Everolimus
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CA protein, human